Rodolfo Cadilla and Philip Turnbull Pages 245 - 270 ( 26 )
Modulation of the androgen receptor has the potential to be an effective treatment for hypogonadism, andropause, and associated conditions such as sarcopenia, osteoporosis, benign prostatic hyperplasia, and sexual dysfunction. Side effects associated with classical anabolic steroid treatments have driven the quest for drugs that demonstrate improved therapeutic profiles. Novel, non-steroidal compounds that show tissue selective activity and improved pharmacokinetic properties have been developed. This review provides an overview of current advances in the development of selective androgen receptor modulators (SARMs).
SARMs, AR, modulation, tissue selectivity, testosterone, dihydrotestosterone, estradiol, hypogonadism
GlaxoSmithKline Inc,Metabolic and Viral Diseases Drug Discovery, Research Triangle Park, POBox 13398, NC 27705, USA.